Efficacy
In the ECHELON-1 trialr, 1334 patients with previously untreated stage III or IV classical Hodgkin lymphoma were randomised to receive either brentuximab vedotin, doxorubicin, vinblastine, dacarbazine (BV-AVD) or doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD). A summary of the efficacy can be seen in the table below.
Study |
Total no. of patients (pts) |
Treatment arm |
Control arm |
Overall survival (at 6 years) |
Progression-free survival (at 6 years) |
ECHELON-1 study 2018r |
1334 pts |
664 pts BV-AVD |
670 pts ABVD |
93.9% (BV-AVD)
vs
89.4% (ABVD)r
|
82.3% (BV-AVD)
vs
74.5% (ABVD)r
|
Three-year progression-free survival (PFS) was 83.1% with BV-AVD, compared to 76.0% with ABVD (HR 0.704, p=0.005). This PFS improvement was seen in patients aged less than 60 years (HR 0.69, p=0.008), with a trend in favour of BV-AVD in patients aged ≥60 years (HR 0.79, p=0.366).r
The six-year overall survival (OS) was 93.9% in the BV-AVD group and 89.4% in the ABVD group, with an overall hazard ratio for death of 0.59 (p=0.009).r
Quality of life data was collected as part of the study but not reported.
Figure 1. Kaplan-Meier estimates of overall survivalr
© The New England Journal of Medicine 2022
Figure 2. Kaplan-Meier estimates of progression-free survivalr
© The New England Journal of Medicine 2022